Global Times, a publication under the Chinese Communist Party’s (CCP’s) mouthpiece People’s Daily, tweeted on March 17:
“#Breaking: Recombinant #COVID19 vaccine developed by the team led by top PLA epidemiologist Chen Wei was approved to launch clinical trials in#China on Monday”
Science Net reported on March 17, that Wang Junzhi, a member of the China Engineering Academy, said at a State Council press conference that China’s vaccine research team has started recruiting volunteers for testing.
“This is an institution which has made fast progress in the development of a vaccine, submitted a clinical trial application to the State Drug Administration and started reviewing the clinical trial plan and recruiting volunteers.” “We are among the leading tier of the countries in novel coronavirus vaccine R&D work and will not be slower than foreign countries.”
Wang said that China picked eight teams to focus on five technical areas when launching the vaccine development work. Most of the teams will complete a pre-trial study in April and gradually start clinical trials afterward. Some team(s) are even faster.
Related postings on Chinascope:
- “World Leader”: Experts: China’s Epidemic Control Model Cannot Be Adopted by Other Countries
- “World Leader”: Taiwan Sets an Example for the World
- “World Leader”: Beijing Released a Documentary “The Lockdown: One Month in Wuhan”
- “World Leader”: Beijing Is Thinking Creating a Beijing-led World Health Organization to Replace WHO
- “World Leader”: Commentary by Minister of Foreign Affairs
1. Source: Twitter
#Breaking: Recombinant #COVID19 vaccine developed by the team led by top PLA epidemiologist Chen Wei was approved to launch clinical trials in #China on Monday pic.twitter.com/ENa3qE4nyD
— Global Times (@globaltimesnews) March 17, 2020
2. Excerpt in Chinese:
3月17日下午，在国务院联防联控机制召开的新闻发布会上，中国工程院院士王军志分享了一个重要进展：
我国新冠病毒疫苗科研团队已开始招募受试者——
“我国已有（疫苗）研发进展比较快的单位，向国家药监局滚动递交临床试验申请材料，并且已经开展临床试验方案论证、招募志愿者等相关工作。待国家药监局按照有关法律法规审批后，开始临床试验。”
“应该说，我国新冠疫苗研发进展目前总体上处于国际先进行列，不会慢于国外。”王军志说。
王军志：
疫情初始我国就成立科研攻关组，第一时间就把疫苗研发纳入到五大攻关方向，予以定向优先支持。紧紧抓住灭活疫苗、基因工程重组亚单位疫苗、腺病毒载体疫苗、减毒流感病毒载体疫苗和核酸疫苗5条技术方向，遴选8个优势团队全力推进疫苗研发。
目前5大技术方向疫苗都总体进展顺利，第一批确定的9项任务都已完成临床前研究（也就是动物的有效性、安全性研究）的大部分工作。大部分研发团队4月份都能完成临床前研究，并逐步启动临床试验，有的团队进展更快。
Source: Science Net, March 17, 2020
http://news.sciencenet.cn/htmlnews/2020/3/437120.shtm